Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor; and RMC-5127, a RAS(ON) G12V-selective inhibitor, are currently in clinical development. As a new member of the Revolution Medicines team, you will join other outstanding professionals in a tireless commitment to patients with cancers harboring mutations in the RAS signaling pathway.
The Opportunity:
Revolution Medicines is seeking a Sr. Financial Analyst/Finance Manager to support our growing needs in Development and R&D Finance. The successful candidate will have experience with clinical trials, R&D accruals process, month-end close, financial reporting, SOX, and audit support. This position is based out of our headquarters in Redwood City, CA.
Reporting to the Associate Director, FP&A and will serve as a business partner to Clinical Operations and cross-functional partner to Accounting, Finance, and Procurement.
Prepare month-end clinical trial accruals, including review of CRO reports, patient costs, and site payments.
Prepare monthly and quarterly reconciliations for accrued clinical and related prepaid accounts.
Contribute to Identify, design, and implement process improvements to streamline clinical trial accruals, reducing manual effort and improving accuracy and timeliness.
Review contracts and amendments to analyze and determine impact on clinical accruals.
Prepare contract analysis to assess new contracts against existing budget.
Work with external CROs and vendors to ensure that expenses are accurately accounted for.
Ensure and maintain proper documentation and internal controls around clinical trial accruals for SOX compliance.
Partner with the accounting team to support monthly and quarterly close activities.
Support the annual audit and quarterly reviews through preparation of audit schedules and other documentation as requested by external auditors.
Perform variance analysis of actuals versus budget, investigate and explain key discrepancies, and identify underlying business drivers.
Prepare actuals vs budget dashboard monthly to provide financial visibility to business partners.
Review purchase requests against budgeted amount and account coding.
Prepare ad hoc financial analysis and special projects as needed.
Required Skills, Experience and Education:
Bachelor's degree in finance, Accounting, or related field.
4+ years’ experience in a similar role in biotechnology industry.
Experience in reviewing clinical contracts (i.e. CRO contracts, Site contracts, protocols, etc.).
Highly proficient in Excel and strong attention to detail.
Prior ERP and financial systems experience: Netsuite, etc.
Strong work ethic and ability to adjust workload based on changing priorities.
Preferred Skills:
CPA or MBA.
Biotech or Big 4 Accounting experience.
Prior experience with clinical trial accruals.
Adaptive Planning (Office Connect) experience a plus.
Coupa experience a plus.
#LI-Hybrid #LI-YG1
The base pay salary range for this full-time position for candidates working onsite at our headquarters in Redwood City, CA is listed below. The range displayed on each job posting is intended to be the base pay salary range for an individual working onsite in Redwood City and will be adjusted for the local market a candidate is based in. Our base pay salary ranges are determined by role, level, and location. Individual base pay salary is determined by multiple factors, including job-related skills, experience, market dynamics, and relevant education or training.
Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Revolution Medicines is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital status, medical condition, and veteran status.
Revolution Medicines takes protection and security of personal data very seriously and respects your right to privacy while using our website and when contacting us by email or phone. We will only collect, process and use any personal data that you provide to us in accordance with our CCPA Notice and Privacy Policy. For additional information, please contact [email protected].
We are aware of recent recruitment scams in which individuals or organizations falsely represent themselves as being affiliated with Revolution Medicines. These scams may appear as false job advertisements or unsolicited contacts through communication or chat platforms, email, phone, or text message.
Please note that Revolution Medicines does not extend unsolicited employment offers and will never ask candidates to provide financial information, purchase equipment, or pay fees as part of the hiring process. All legitimate communication from Revolution Medicines will come from an official @revmed.com email address.
If you believe you’ve been contacted by someone impersonating a Revolution Medicines recruiter, please report it to [email protected] so we can share these impersonations with our IT team for tracking and awareness.
Skills Required
- Bachelor's degree in finance, Accounting, or related field
- 4+ years' experience in a similar role in biotechnology industry
- Experience in reviewing clinical contracts
- Highly proficient in Excel
- Prior ERP and financial systems experience: Netsuite
What We Do
We are Revolutionaries – passionate in our singular pursuit of discovering, developing and delivering innovative, targeted medicines for patients living with cancer. To deliver on our vision, we work relentlessly in pursuit of cutting-edge therapeutic approaches to some of the toughest cancers. Our current focus is on RAS-addicted cancers, which account for 30 percent of all new human cancer diagnoses
